16,560 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Strive Asset Management LLC

Strive Asset Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 16,560 shares of the biopharmaceutical company’s stock, valued at approximately $439,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tang Capital Management LLC increased its holdings in shares of Pfizer by 66.7% during the fourth quarter. Tang Capital Management LLC now owns 42,908 shares of the biopharmaceutical company’s stock worth $1,138,000 after purchasing an additional 17,170 shares during the period. Thornburg Investment Management Inc. grew its position in Pfizer by 11.9% during the fourth quarter. Thornburg Investment Management Inc. now owns 9,895,877 shares of the biopharmaceutical company’s stock worth $262,538,000 after buying an additional 1,053,703 shares in the last quarter. Toronto Dominion Bank increased its stake in Pfizer by 62.3% during the 4th quarter. Toronto Dominion Bank now owns 4,695,774 shares of the biopharmaceutical company’s stock worth $124,578,000 after acquiring an additional 1,802,005 shares during the period. Sender Co & Partners Inc. raised its holdings in Pfizer by 29.8% in the 4th quarter. Sender Co & Partners Inc. now owns 11,056 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 2,535 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in Pfizer in the 4th quarter valued at $1,329,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Performance

NYSE PFE opened at $22.83 on Friday. The company has a market capitalization of $129.77 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a 50-day simple moving average of $23.65 and a 200 day simple moving average of $25.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. Pfizer’s revenue was down 7.8% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.